Aurinia Pharmaceuticals (AUPH) CFO Michael Hearne becomes reporting insider with Form 3

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. disclosed that Michael S. Hearne, its Chief Financial Officer, filed an initial Form 3 as a reporting person. This filing establishes his insider status for future ownership and transaction reporting but does not list any specific share holdings or recent trades.

Key Terms

Form 3, Chief Financial Officer, reporting person

3 terms

Form 3 regulatory

"filed an initial Form 3 as a reporting person"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Financial Officer financial

"Michael S. Hearne, its Chief Financial Officer, filed"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reporting person regulatory

"filed an initial Form 3 as a reporting person"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hearne Michael S

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON T5L 4S6

(City) (State) (Zip)

ALBERTA, CANADA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Michael Hearne	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Aurinia Pharmaceuticals (AUPH) Form 3 filing show for Michael S. Hearne?

The Form 3 identifies Michael S. Hearne as Chief Financial Officer and a reporting person for Aurinia Pharmaceuticals. It serves as his initial beneficial ownership statement but, in this instance, does not report any specific stock or option positions or recent transactions.

Is Aurinia Pharmaceuticals CFO Michael S. Hearne buying or selling AUPH shares in this Form 3?

No, this Form 3 does not report any purchases, sales, option exercises, gifts, or other transactions. It simply designates Michael S. Hearne, the Chief Financial Officer, as an insider whose future trades in Aurinia Pharmaceuticals securities must be reported on Forms 4 or 5.

Why is Aurinia Pharmaceuticals (AUPH) filing a Form 3 for its Chief Financial Officer?

Form 3 is required when someone becomes a reporting insider of a public company. Here, Aurinia Pharmaceuticals filed it to register Chief Financial Officer Michael S. Hearne as a reporting person, establishing a baseline before any future reportable transactions in AUPH securities occur.

Does the Aurinia Pharmaceuticals Form 3 disclose any derivative securities for Michael S. Hearne?

No derivative securities are listed for Michael S. Hearne in this Form 3. The derivative summary is empty, meaning there are no reportable options, warrants, or similar instruments disclosed for the Aurinia Pharmaceuticals Chief Financial Officer in this particular filing.

What transaction activity is summarized in Michael S. Hearne’s Form 3 for Aurinia Pharmaceuticals?

The transaction summary shows zero buys, zero sells, and no other forms of transactions. For Aurinia Pharmaceuticals’ Chief Financial Officer, this Form 3 functions purely as an initial registration of insider status, without any accompanying trading or ownership changes disclosed.